Literature DB >> 10560742

3-Amidinophenylalanine-based inhibitors of urokinase.

J Stürzebecher1, H Vieweg, T Steinmetzer, A Schweinitz, M T Stubbs, M Renatus, P Wikström.   

Abstract

Synthesis and anti-uPA activity of a series of Nalpha-triisopropyl-phenylsulfonyl-protected 3-amidinophenylalanine amides are described. We have explored SAR around the C-terminal amide part for inhibition of uPA, plasmin and trypsin. Modification of the amide part has been found to affect potency but not selectivity. With a Ki of 0.41 microM 2r-L is one of the most potent uPA inhibitors described so far. The X-ray crystal structure of 2r-L was solved in complex with trypsin, superimposed with uPA and the results suggest an unique binding mode of this inhibitor type.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10560742     DOI: 10.1016/s0960-894x(99)00541-7

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  12 in total

1.  RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth.

Authors:  Shakuntala Kondraganti; Christopher S Gondi; Ian McCutcheon; Dzung H Dinh; Meena Gujrati; Jasti S Rao; William C Olivero
Journal:  Int J Oncol       Date:  2006-06       Impact factor: 5.650

2.  Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth.

Authors:  Christopher S Gondi; Sajani S Lakka; Dzung H Dinh; William C Olivero; Meena Gujrati; Jasti S Rao
Journal:  Neuron Glia Biol       Date:  2004-05

3.  Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.

Authors:  Mahmoud A Al-Sha'er; Mohammad A Khanfar; Mutasem O Taha
Journal:  J Mol Model       Date:  2014-01-28       Impact factor: 1.810

4.  6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.

Authors:  Benjamin J Buckley; Ashraf Aboelela; Elahe Minaei; Longguang X Jiang; Zhihong Xu; Umar Ali; Karen Fildes; Chen-Yi Cheung; Simon M Cook; Darren C Johnson; Daniel A Bachovchin; Gregory M Cook; Minoti Apte; Mingdong Huang; Marie Ranson; Michael J Kelso
Journal:  J Med Chem       Date:  2018-09-07       Impact factor: 7.446

5.  (4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase.

Authors:  S Sperl; U Jacob; N Arroyo de Prada; J Stürzebecher; O G Wilhelm; W Bode; V Magdolen; R Huber; L Moroder
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

Review 6.  Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity.

Authors:  Nehad S El Salamouni; Benjamin J Buckley; Marie Ranson; Michael J Kelso; Haibo Yu
Journal:  Biophys Rev       Date:  2022-01-06

7.  Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis.

Authors:  Pamela Zengel; Diana Ramp; Brigitte Mack; Stefan Zahler; Alexander Berghaus; Bernd Muehlenweg; Olivier Gires; Suna Schmitz
Journal:  BMC Cancer       Date:  2010-03-11       Impact factor: 4.430

8.  Reducing tumor growth and angiogenesis using a triple therapy measured with Contrast-enhanced ultrasound (CEUS).

Authors:  Philipp Marius Paprottka; Svenja Roßpunt; Michael Ingrisch; Clemens C Cyran; Konstantin Nikolaou; Maximilian F Reiser; Brigitte Mack; Olivier Gires; Dirk A Clevert; Pamela Zengel
Journal:  BMC Cancer       Date:  2015-05-08       Impact factor: 4.430

Review 9.  Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders.

Authors:  Rami A Al-Horani; Umesh R Desai
Journal:  Med Res Rev       Date:  2014-03-21       Impact factor: 12.944

10.  3-Amidinophenylalanine-derived matriptase inhibitors can modulate hepcidin production in vitro.

Authors:  Erzsébet Pászti-Gere; Gergely Szombath; Michael Gütschow; Torsten Steinmetzer; András Székács
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-10-28       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.